|
WO2021055528A1
|
|
Methods and kit for analyzing responsiveness of patients to cd19 immunotherapy
|
|
WO2021041299A1
|
|
Method and kit for determining benefit of chemotherapy
|
|
WO2021034920A1
|
|
SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY
|
|
WO2021016425A1
|
|
Mirnas for reducing ventricle enlargement
|
|
WO2021016091A1
|
|
Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors
|
|
WO2020219682A2
|
|
Gene knock-outs to improve t cell function
|
|
WO2020210665A1
|
|
Chimeric antigen receptors with cd20 safety switch
|
|
WO2020210365A1
|
|
Dnmt3a knock-out and stat5 activated genetically engineered t-cells
|
|
WO2020222987A1
|
|
T cell gene expression analysis for use in t cell therapies
|
|
WO2020186110A1
|
|
Small molecules that bind cyclin-dependent kinase inhibitor 1b (p27kip1)
|
|
WO2020097065A1
|
|
Methods and compositions for prodrug forms of spectinomycin and spectinamide analogs
|
|
WO2019222579A1
|
|
Chimeric antigen receptors with myd88 and cd40 costimulatory domains
|
|
WO2019217785A1
|
|
High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro
|
|
KR20200123156A
|
|
Hu14.18K322A monoclonal antibody production process
|
|
EP3746564A1
|
|
Method for nucleic acid amplification
|
|
US2021023081A1
|
|
Methods of treating disorders associated with castor
|
|
WO2019084365A1
|
|
Methods and formulations for treatment of spinobulbar muscular atrophy
|
|
US2021030793A1
|
|
Methods and compositions for treating cd33+ cancers and improving in vivo persistence of chimeric antigen receptor t cells
|
|
US2019040381A1
|
|
Cloning and expression system for t-cell receptors
|
|
US2018030453A1
|
|
Method for improving learning
|
